Ismaila AS, et al. – In this trial, healthcare resource utilization was evaluated in patients with symptomatic chronic obstructive pulmonary disease at risk of exacerbations. The accumulated evidence demonstrated that, in a clinical trial setting over a 24- or 52-week timeframe, non-drug costs associated with management of a single inhaler fluticasone furoate/umeclidinium/vilanterol were lower compared with twice-daily budesonide/formoterol.